Drug Trial Radar · NCT04799327
The Effect of SHR20004(Noiiglutide ) on Body Weight in Obese Subjects Without Diabetes
Last checked: Nov 20, 2026Latest source record: Mar 15, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
254
Actual
Start
Mar 29, 2021
Primary completion
May 15, 2022
Study completion May 15, 2022
Sponsor
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 16, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is being conducted to assess the efficacy and safety of SHR20004 on body weight in obese subjects without diabetes.
Conditions
- Obesity
Interventions
SHR20004Drug
SHR20004:low dose
SHR20004Drug
SHR20004: medium dose
SHR20004Drug
SHR20004: high dose
placeboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in body weightTime frame: Week 0, Week 24
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Chinese PLA General Hospital
Beijing, Beijing Municipality, China
Shanxi Provincial People's Hospital
Taiyuan, Shanxi, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.